Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biogen
Biotech
Biogen advances Alzheimer’s tau program despite midphase miss
While the study failed to yield the hoped-for dose-response data, reductions in tau and cognitive benefits led Biogen to commit to a pivotal trial.
Nick Paul Taylor
May 14, 2026 8:35am
Biogen inks $850M deal with TJ for China rights antibody
Apr 20, 2026 10:26am
Biogen links up with Alloy platform to boost ASO drug development
Apr 7, 2026 6:00am
Biogen’s litifilimab sparkles in midphase lupus trial
Mar 30, 2026 4:45am
Stoke aims to restore developmental loss in Dravet syndrome
Mar 18, 2026 2:57pm
Novartis jettisons ph. 1 cancer candidate after 0% efficacy
Feb 19, 2026 2:45pm
